Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.57 USD | +9.03% | +6.08% | +0.64% |
04-25 | Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment | MT |
04-25 | Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment | DJ |
Evolution of the average Target Price on Compass Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Compass Therapeutics, Inc.
Jefferies & Co. | |
Stifel Nicolaus | |
EF Hutton | |
Raymond James | |
HC Wainwright | |
SVB Leerink | |
Ladenburg Thalmann | |
B. Riley | |
Wedbush | |
Roth Capital Partners |
EPS Revisions
- Stock Market
- Equities
- CMPX Stock
- Consensus Compass Therapeutics, Inc.